Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1

Virology

Volumn 432, Issue 2, 2012, Pages 283-295

  Ugai, Hideyo ^a   Dobbins, George C ^a   Wang, Minghui ^a   Le, Long P ^c   Matthews, David A ^d   Curiel, David T ^a,b  

^a and Clinical Center   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adenoviral assembly; Adenovirus; Cancer gene therapy; Nucleophosmin 1; Protein V

Indexed keywords

NUCLEOPHOSMIN; VIRUS PROTEIN V;

ADENOVIRUS; ARTICLE; CANCER CELL; CELL NUCLEOPLASM; CELL NUCLEUS; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; MUTANT; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TRANSPORT; VIROGENESIS; VIRUS ASSEMBLY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; CELL LINE; CELL NUCLEOLUS; NUCLEAR PROTEINS; VIRAL CORE PROTEINS; VIRUS ASSEMBLY; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84865301824     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.05.028     Document Type: Article

References (77)

1. Anderson C.W., Young M.E., Flint S.J. Characterization of the adenovirus 2 virion protein, mu. Virology 1989, 172(2):506-512.
2. Andersson M.G., Haasnoot P.C., Xu N., Berenjian S., Berkhout B., Akusjarvi G. Suppression of RNA interference by adenovirus virus-associated RNA. J. Virol. 2005, 79(15):9556-9565.
3. Barker D.D., Berk A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987, 156(1):107-121.
4. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274(5286):373-376.
5. Bodnar J.W., Hanson P.I., Polvino-Bodnar M., Zempsky W., Ward D.C. The terminal regions of adenovirus and minute virus of mice DNAs are preferentially associated with the nuclear matrix in infected cells. J. Virol. 1989, 63(10):4344-4353.
6. Carson C.T., Schwartz R.A., Stracker T.H., Lilley C.E., Lee D.V., Weitzman M.D. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J. 2003, 22(24):6610-6620.
7. Chatterjee P.K., Vayda M.E., Flint S.J. Interactions among the three adenovirus core proteins. J. Virol. 1985, 55(2):379-386.
8. Chatterjee P.K., Vayda M.E., Flint S.J. Identification of proteins and protein domains that contact DNA within adenovirus nucleoprotein cores by ultraviolet light crosslinking of oligonucleotides 32 P-labelled in vivo. J. Mol. Biol. 1986, 188(1):23-37.
9. Colombo E., Marine J.C., Danovi D., Falini B., Pelicci P.G. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol. 2002, 4(7):529-533.
10. Dalenc F., Drouet J., Ader I., Delmas C., Rochaix P., Favre G., Cohen-Jonathan E., Toulas C. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int. J. Cancer 2002, 100(6):662-668.
11. Davison A.J., Benko M., Harrach B. Genetic content and evolution of adenoviruses. J. Gen. Virol. 2003, 84(Pt 11):2895-2908.
12. de Vries W., Berkhout B. RNAi suppressors encoded by pathogenic human viruses. Int. J. Biochem. Cell Biol. 2008, 40(10):2007-2012.
13. Delenda C., Gaillard C. Real-time quantitative PCR for the design of lentiviral vector analytical assays. Gene Ther. 2005, 12(Suppl 1):S36-S50.
14. Edvardsson B., Everitt E., Jornvall H., Prage L., Philipson L. Intermediates in adenovirus assembly. J. Virol. 1976, 19(2):533-547.
15. Fukuda K., Abei M., Ugai H., Seo E., Wakayama M., Murata T., Todoroki T., Tanaka N., Hamada H., Yokoyama K.K. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 2003, 63(15):4434-4440.
16. Gallinaro H., Puvion E., Kister L., Jacob M. Nuclear matrix and hnRNP share a common structural constituent associated with premessenger RNA. EMBO J. 1983, 2(6):953-960.
17. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat. Rev. Cancer 2006, 6(7):493-505.
18. Harada J.N., Berk A.J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 1999, 73(7):5333-5344.
19. Herrera J.E., Savkur R., Olson M.O. The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res. 1995, 23(19):3974-3979.
20. Hindley C.E., Davidson A.D., Matthews D.A. Relationship between adenovirus DNA replication proteins and nucleolar proteins B23.1 and B23.2. J. Gen. Virol. 2007, 88(Pt 12):3244-3248.
21. Hingorani K., Szebeni A., Olson M.O. Mapping the functional domains of nucleolar protein B23. J. Biol. Chem. 2000, 275(32):24451-24457.
22. Hiscox J.A. The nucleolus-a gateway to viral infection?. Arch. Virol. 2002, 147(6):1077-1089.
23. Imperiale M.J., Feldman L.T., Nevins J.R. Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element. Cell 1983, 35(1):127-136.
24. Ishibashi M., Maizel J.V. The polypeptides of adenovirus. V. Young virions, structural intermediate between top components and aged virions. Virology 1974, 57(2):409-424.
25. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell. 2003, 12(5):1151-1164.
26. Karni-Schmidt O., Friedler A., Zupnick A., McKinney K., Mattia M., Beckerman R., Bouvet P., Sheetz M., Fersht A., Prives C. Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene 2007, 26(26):3878-3891.
27. Koch P., Gatfield J., Lober C., Hobom U., Lenz-Stoppler C., Roth J., Dobbelstein M. Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. Cancer Res. 2001, 61(15):5941-5947.
28. Kurki S., Peltonen K., Latonen L., Kiviharju T.M., Ojala P.M., Meek D., Laiho M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004, 5(5):465-475.
29. Lam, Y.W., Evans, V.C., Heesom, K.J., Lamond, A.I., and Matthews, D.A. (2009). Proteomic analysis of the nucleolus in adenovirus-infected cells. Mol. Cell Proteomics.
30. Lawrence F.J., McStay B., Matthews D.A. Nucleolar protein upstream binding factor is sequestered into adenovirus DNA replication centres during infection without affecting RNA polymerase I location or ablating rRNA synthesis. J. Cell Sci. 2006, 119(Pt 12):2621-2631.
31. Le L.P., Le H.N., Dmitriev I.P., Davydova J.G., Gavrikova T., Yamamoto S., Curiel D.T., Yamamoto M. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J. Natl. Cancer Inst. 2006, 98(3):203-214.
32. Le L.P., Le H.N., Nelson A.R., Matthews D.A., Yamamoto M., Curiel D.T. Core labeling of adenovirus with EGFP. Virology 2006, 351(2):291-302.
33. Le Moullec J.M., Akusjarvi G., Stalhandske P., Pettersson U., Chambraud B., Gilardi P., Nasri M., Perricaudet M. Polyadenylic acid addition sites in the adenovirus type 2 major late transcription unit. J. Virol. 1983, 48(1):127-134.
34. Lee C., Smith B.A., Bandyopadhyay K., Gjerset R.A. DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 2005, 65(21):9834-9842.
35. Lee J.H., Paull T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308(5721):551-554.
36. Lee T.W., Lawrence F.J., Dauksaite V., Akusjarvi G., Blair G.E., Matthews D.A. Precursor of human adenovirus core polypeptide Mu targets the nucleolus and modulates the expression of E2 proteins. J. Gen. Virol. 2004, 85(Pt 1):185-196.
37. Lehmberg E., Traina J.A., Chakel J.A., Chang R.J., Parkman M., McCaman M.T., Murakami P.K., Lahidji V., Nelson J.W., Hancock W.S., Nestaas E., Pungor E. Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome. J. Chromatogr. B 1999, 732(2):411-423.
38. Levine A.J. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 2009, 384(2):285-293.
39. Lu S., Cullen B.R. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J. Virol. 2004, 78(23):12868-12876.
40. Mattern K.A., Humbel B.M., Muijsers A.O., de Jong L., van Driel R. hnRNP proteins and B23 are the major proteins of the internal nuclear matrix of HeLa S3 cells. J. Cell Biochem. 1996, 62(2):275-289.
41. Matthews D.A. Adenovirus protein V induces redistribution of nucleolin and B23 from nucleolus to cytoplasm. J. Virol. 2001, 75(2):1031-1038.
42. Matthews D.A., Russell W.C. Adenovirus core protein V is delivered by the invading virus to the nucleus of the infected cell and later in infection is associated with nucleoli. J. Gen. Virol. 1998, 79(Pt 7):1671-1675.
43. Nevins J.R. Regulation of early adenovirus gene expression. Microbiol. Rev. 1987, 51(4):419-430.
44. Nozawa Y., Van Belzen N., Van der Made A.C., Dinjens W.N., Bosman F.T. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J. Pathol. 1996, 178(1):48-52.
45. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., Boyle L., Pandey K., Soria C., Kunich J., Shen Y., Habets G., Ginzinger D., McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6(6):611-623.
46. Okuwaki M., Iwamatsu A., Tsujimoto M., Nagata K. Identification of nucleophosmin/B23, an acidic nucleolar protein, as a stimulatory factor for in vitro replication of adenovirus DNA complexed with viral basic core proteins. J. Mol. Biol. 2001, 311(1):41-55.
47. Ostapchuk P., Hearing P. Control of adenovirus packaging. J. Cell Biochem. 2005, 96(1):25-35.
48. Palaniswamy V., Moraes K.C., Wilusz C.J., Wilusz J. Nucleophosmin is selectively deposited on mRNA during polyadenylation. Nat. Struct. Mol. Biol. 2006, 13(5):429-435.
49. Querido E., Marcellus R.C., Lai A., Charbonneau R., Teodoro J.G., Ketner G., Branton P.E. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 1997, 71(5):3788-3798.
50. Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003, 22(22):6068-6077.
51. Sagawa, F., Ibrahim, H., Morrison, A.L., Wilusz, C.J., and Wilusz, J. (2011). Nucleophosmin deposition during mRNA 3' end processing influences poly(A) tail length. EMBO J.
52. Saito I., Oya Y., Yamamoto K., Yuasa T., Shimojo H. Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J. Virol. 1985, 54(3):711-719.
53. Sargent K.L., Meulenbroek R.A., Parks R.J. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J. Virol. 2004, 78(10):5032-5037.
54. Sastry L., Johnson T., Hobson M.J., Smucker B., Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 2002, 9(17):1155-1162.
55. Sauthoff H., Pipiya T., Heitner S., Chen S., Norman R.G., Rom W.N., Hay J.G. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum. Gene Ther. 2002, 13(15):1859-1871.
56. Sautkina E.N., Potapenko N.A., Bulycheva T.I., Vladimirova N.M. [Isolation of the protein B23/nucleophosmin from HeLa cell nuclei]. Prikl Biokhim Mikrobiol. 2008, 44(3):287-295.
57. Savkur R.S., Olson M.O. Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 1998, 26(19):4508-4515.
58. Schaack J., Ho W.Y., Freimuth P., Shenk T. Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev. 1990, 4(7):1197-1208.
59. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6(9):663-673.
60. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2(2):103-112.
61. Somasundaram K., El-Deiry W.S. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 1997, 14(9):1047-1057.
62. Soria C., Estermann F.E., Espantman K.C., O'Shea C.C. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 2010, 466(7310):1076-1081.
63. Steinwaerder D.S., Carlson C.A., Lieber A. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes. Mol. Ther. 2001, 4(3):211-216.
64. Subong E.N., Shue M.J., Epstein J.I., Briggman J.V., Chan P.K., Partin A.W. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999, 39(4):298-304.
65. Tibbetts C., Giam C.Z. In vitro association of empty adenovirus capsids with double-stranded DNA. J. Virol. 1979, 32(3):995-1005.
66. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6(12):909-923.
67. Ugai H., Borovjagin A.V., Le L.P., Wang M., Curiel D.T. Thermostability/infectivity defect caused by deletion of the core protein V gene in human adenovirus type 5 is rescued by thermo-selectable mutations in the core protein X precursor. J. Mol. Biol. 2007, 366(4):1142-1160.
68. Ugai H., Wang M., Le L.P., Matthews D.A., Yamamoto M., Curiel D.T. In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection. J. Mol. Biol. 2010, 395(1):55-78.
69. Ugai H., Yamasaki T., Hirose M., Inabe K., Kujime Y., Terashima M., Liu B., Tang H., Zhao M., Murata T., Kimura M., Pan J., Obata Y., Hamada H., Yokoyama K.K. Purification of infectious adenovirus in two hours by ultracentrifugation and tangential flow filtration. Biochem. Biophys. Res. Commun. 2005, 331(4):1053-1060.
70. van Oostrum J., Burnett R.M. Molecular composition of the adenovirus type 2 virion. J. Virol. 1985, 56(2):439-448.
71. Vayda M.E., Rogers A.E., Flint S.J. The structure of nucleoprotein cores released from adenovirions. Nucleic Acids Res. 1983, 11(2):441-460.
72. Walton T.H., Moen P.T., Fox E., Bodnar J.W. Interactions of minute virus of mice and adenovirus with host nucleoli. J. Virol. 1989, 63(9):3651-3660.
73. Wang D., Umekawa H., Olson M.O. Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. Cell Mol. Biol. Res. 1993, 39(1):33-42.
74. Xu N., Segerman B., Zhou X., Akusjarvi G. Adenovirus virus-associated RNAII-derived small RNAs are efficiently incorporated into the rna-induced silencing complex and associate with polyribosomes. J. Virol. 2007, 81(19):10540-10549.
75. Yung B.Y., Chan P.K. Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. Biochim. Biophys. Acta 1987, 925(1):74-82.
76. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92(6):725-734.
77. Zink D., Fischer A.H., Nickerson J.A. Nuclear structure in cancer cells. Nat. Rev. Cancer 2004, 4(9):677-687.